ESAs, Erythropoiesis-Stimulating Agents
0.6mg dose: 6.2% average weight loss 2.4mg dose: 12.5% average weight loss 3.6mg dose: 13.2% average weight loss 4.8mg dose: 14.9% average weight loss (planned treatment analysis) 4.8mg dose: 18.7% average weight loss (actual treatment received analysis) Placebo: 2.8% average weight loss The distinction between planned treatment and actual treatment received analyses matters
Zhang Y, Chang QC, Zhang Y, Na L, Wang WT, Xu WW, Gao DZ, Liu ZX, Wang CR, Zhu XQ
Its released in bursts every 3 5 hours
Menstrual cycles are sensitive to energy balance, especially over time
Furthermore, the consistent reduction in the risk of MACEs and MAKEs observed with GLP-1 RAs use across patient subgroups underscores the potential of these agents in managing cardiorenal risk